New combo therapy targets brain tumor in early trial
NCT ID NCT03011671
First seen Apr 25, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This early-phase study tests whether adding the drug acetazolamide to standard chemotherapy (temozolomide) is safe for people with a newly diagnosed, aggressive brain cancer called glioblastoma. Only 10 participants with a specific genetic marker (MGMT promoter methylation) are enrolled. The main goal is to check for side effects, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA OF BRAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.